Cargando…
Les antipsychotiques de la future décade()
Antipsychotic drugs are one of the oldest drugs that can change the brain activity. These drugs are mainly used in schizophrenia and the first drug that was judged as efficacious in the treatment of psychosis has been chlorpromazine. This is a decade later that it has been shown that these drugs wer...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553002/ https://www.ncbi.nlm.nih.gov/pubmed/33071288 http://dx.doi.org/10.1016/j.banm.2020.10.005 |
_version_ | 1783593517802586112 |
---|---|
author | Guillin, O. |
author_facet | Guillin, O. |
author_sort | Guillin, O. |
collection | PubMed |
description | Antipsychotic drugs are one of the oldest drugs that can change the brain activity. These drugs are mainly used in schizophrenia and the first drug that was judged as efficacious in the treatment of psychosis has been chlorpromazine. This is a decade later that it has been shown that these drugs were antagonists at the dopamine transmission by blocking the dopamine D2/D3 receptors. Several other pharmacological targets have been tested during the last decades as glutamatergic, serotoninergic, cholinergic and neuropeptidergic agents but none has been shown to improve symptoms of schizophrenia. Three main issues could explain this failure: the exact causes of schizophrenia is still unknown, we still used the idea that one drug could improve all the symptoms of schizophrenia and it is clear that the group of schizophrenics disease could be different disease with different causes. We propose to review the different drugs that have been tested and we will discuss why the most recent genetic studies could help us to propose new pharmacological targets to treat schizophrenia. |
format | Online Article Text |
id | pubmed-7553002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75530022020-10-13 Les antipsychotiques de la future décade() Guillin, O. Bull Acad Natl Med Revue Générale Antipsychotic drugs are one of the oldest drugs that can change the brain activity. These drugs are mainly used in schizophrenia and the first drug that was judged as efficacious in the treatment of psychosis has been chlorpromazine. This is a decade later that it has been shown that these drugs were antagonists at the dopamine transmission by blocking the dopamine D2/D3 receptors. Several other pharmacological targets have been tested during the last decades as glutamatergic, serotoninergic, cholinergic and neuropeptidergic agents but none has been shown to improve symptoms of schizophrenia. Three main issues could explain this failure: the exact causes of schizophrenia is still unknown, we still used the idea that one drug could improve all the symptoms of schizophrenia and it is clear that the group of schizophrenics disease could be different disease with different causes. We propose to review the different drugs that have been tested and we will discuss why the most recent genetic studies could help us to propose new pharmacological targets to treat schizophrenia. Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. 2020-12 2020-10-13 /pmc/articles/PMC7553002/ /pubmed/33071288 http://dx.doi.org/10.1016/j.banm.2020.10.005 Text en © 2020 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Revue Générale Guillin, O. Les antipsychotiques de la future décade() |
title | Les antipsychotiques de la future décade() |
title_full | Les antipsychotiques de la future décade() |
title_fullStr | Les antipsychotiques de la future décade() |
title_full_unstemmed | Les antipsychotiques de la future décade() |
title_short | Les antipsychotiques de la future décade() |
title_sort | les antipsychotiques de la future décade() |
topic | Revue Générale |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553002/ https://www.ncbi.nlm.nih.gov/pubmed/33071288 http://dx.doi.org/10.1016/j.banm.2020.10.005 |
work_keys_str_mv | AT guillino lesantipsychotiquesdelafuturedecade |